Repatha vs Brilinta
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
| Attribute | US Repatha | US Brilinta |
|---|---|---|
| Generic name | evolocumab Unverified catalogue summary (Generic name) for Repatha in US; not checked against current local product information. | ticagrelor Unverified catalogue summary (Generic name) for Brilinta in US; not checked against current local product information. |
| Drug class | See official local label Unverified catalogue summary (Drug class) for Repatha in US; not checked against current local product information. | See official local label Unverified catalogue summary (Drug class) for Brilinta in US; not checked against current local product information. |
| Treats | High cholesterol, cardiovascular disease Unverified catalogue summary (Treats) for Repatha in US; not checked against current local product information. | Acute coronary syndrome, heart attack prevention Unverified catalogue summary (Treats) for Brilinta in US; not checked against current local product information. |
| Category | Cardiovascular Unverified catalogue summary (Category) for Repatha in US; not checked against current local product information. | Cardiovascular Unverified catalogue summary (Category) for Brilinta in US; not checked against current local product information. |
| Manufacturer | Amgen Unverified catalogue summary (Manufacturer) for Repatha in US; not checked against current local product information. | AstraZeneca Pharmaceuticals LP (US distributor) Unverified catalogue summary (Manufacturer) for Brilinta in US; not checked against current local product information. |
| Year approved | — Unverified catalogue summary (Year approved) for Repatha in US; not checked against current local product information. | — Unverified catalogue summary (Year approved) for Brilinta in US; not checked against current local product information. |
| Catalogue warning level | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Repatha in US; not checked against current local product information. | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Brilinta in US; not checked against current local product information. |
| Est. TV ad spend | $120M | $120M |
| Side effects and serious risks | — Unverified catalogue summary (Side effects and serious risks) for Repatha in US; not checked against current local product information. | — Unverified catalogue summary (Side effects and serious risks) for Brilinta in US; not checked against current local product information. |
Sources and editorial standards
Use the current DailyMed labels to verify approved uses, boxed warnings, and side effects for each medication. Label results can differ by product, strength, and formulation.
Page updated November 4, 2026; the linked resources have not necessarily been reviewed on this date.
Frequently asked questions
Is Repatha or Brilinta better?
This directory does not compare clinical effectiveness or safety. Listing Repatha and Brilinta together does not establish shared approved indications, equivalence or suitability as substitutes. Consult the correct local labels and your prescriber.
What's the difference between Repatha and Brilinta?
The table shows catalogue identification and estimated advertising information for Repatha and Brilinta, not a verified medical comparison. Medical descriptions, mechanisms and safety summaries are withheld.
Which one spends more on TV ads?
Repatha has the larger estimated TV advertising budget of the two.